AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01595425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H Sachet 20 mg
Description: Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
Study NCT01595425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H HPMC capsule 20 mg
Description: Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
Study NCT01190436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
Study NCT00119782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A dietary intervention that will promote lower calorie intake
Study NCT00119782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A physical activity intervention combining increased daily physical activity and regular, structured exercise
Study NCT00863265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
Study NCT00863265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytosterols + ezetimibe
Description: Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
Study NCT00863265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03661645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg IV dexamethasone & 6 day oral methylprednisolone taper
Description: Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone
Study NCT03661645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 10 mg IV dexamethasone
Description: Drug:10 mg intravenous (IV) dexamethasone
Study NCT01744639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCC under treatment with radioablation
Description: The evaluation will take place over a period of 30 days.
Study NCT03985540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavorial; memory exercise
Description: Memory training twice a week for 5 weeks.
Study NCT03985540 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; memory exercise
Description: Placebo Memory training twice a week for 5 weeks
Study NCT03985540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: speed exercises
Description: Speed training twice a week for 5 weeks.
Study NCT03985540 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo speed training
Description: Placebo Speed training twice a week for 5 weeks.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chestnut honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT01077401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
Study NCT01077401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
Study NCT04063163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Study NCT04063163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and etoposide
Description: chemotherapeutics
Study NCT04063163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin and etoposide
Description: chemotherapeutics
Study NCT04063163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02781480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV RPE65
Description: Comparison of different dosages of AAV RPE65
Study NCT03661333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
Study NCT01848327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride
Description: Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
Study NCT01848327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (40 gram packet orally once a day for 90 days)
Study NCT01483183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-108459
Description: Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1
Study NCT01483183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-108459
Description: Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1
Study NCT01483183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose, 10-minute constant rate IV infusion
Study NCT03312842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type.
Study NCT04375059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: using interactive attention training system
Description: using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
Study NCT00932412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLARA
Description: Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
Study NCT00932412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDAc
Description: Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
Study NCT01966835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
Study NCT00466921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
Study NCT02742376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Soft surface
Description: A sponge rectangle used in physiotherapy will be placed on the floor,
Study NCT02742376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Floor
Description: A marked path on the floor where the subject is instructed to walk.
Study NCT02742376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kyboot shoes
Description: Special shoes will be worn by the subject.
Study NCT00998088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: erythropoietin and cell saver
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
Study NCT00998088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively
Study NCT00998088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: for intra- and post-operative re-infusion of autologous wound blood
Study NCT00998088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-operative drain device
Description: For post-operative re-infusion of unwashed wound blood
Study NCT00998088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin and OrthoPAT
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively
Study NCT00998088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin and drain device
Description: weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
Study NCT00998088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: For intra- and post-operative reinfusion of autologous blood
Study NCT01957371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Yoga Therapy
Description: Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and sodium bicarbonate
Description: Lidocaine and sodium bicarbonate ratio 3:1
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and sodium bicarbonate
Description: Lidocaine and sodium bicarbonate ratio 9:1
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection
Study NCT02190799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
Study NCT03411876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® pendant nasal cannula
Description: Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
Study NCT03411876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional nasal cannula
Description: Supplemental oxygen is provided by a conventional nasal cannula.
Study NCT03995212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 1.0 mg
Description: Oral CR845 1.0 mg administered twice daily
Study NCT03995212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered twice daily
Study NCT03947151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix injection(s)
Description: 1 or 2 degarelix injection(s)
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium cloride 0.9%
Description: Placebo
Study NCT03238625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium cloride 0.9%
Description: Placebo
Study NCT00235144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-coated Bx Velocity stent
Description: drug-eluting stent
Study NCT00235144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated Bx Velocity stent
Description: bare-metal stent
Study NCT01511068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukine
Description: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Study NCT01821859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
Study NCT01821859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
Study NCT04215900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-speed yoga multi-directional yoga
Description: The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
Study NCT00555672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT00555672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT00555672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT03079089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sequential Packaging (SET)
Description: Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
Study NCT03079089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Transfusion graft
Description: Graft of peripheral stem cells is preferred at DO
Study NCT03079089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prevention of GVHD
Description: * Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)
Study NCT03079089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Care supports
Description: According to the protocols of each center
Study NCT03079089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lymphocyte injection of prophylactic donor (PDLI)
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II.
Study NCT02540954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: A dose of 2 mg aflibercept injected intravitreally
Study NCT01145339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactase
Description: 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
Study NCT01145339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactase
Description: 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
Study NCT01359943 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).
Study NCT01359943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).
Study NCT01539473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA with Tyramine
Description: TR-701 FA 200 mg oral and Tyramine
Study NCT02540954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: A dose of 2 mg aflibercept injected intravitreally
Study NCT01359943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..
Study NCT01359943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..
Study NCT03925727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavilermide ophthalmic solution
Description: BID topical dosing
Study NCT03623568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir tablets
Description: 12 weeks of treatment with Mavyret
Study NCT03722524 — intervention group
Intervention type: DRUG
Intervention: amlodipine / indapamide / perindopril arginine FDC
Description: CCB / diuretic / ACE inhibitor
Study NCT03925727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID topical dosing